Improving Outcomes in Advanced Malignant Melanoma
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 65 (6) , 733-743
- https://doi.org/10.2165/00003495-200565060-00002
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrenceInternational Journal of Cancer, 2004
- Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2004
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004
- Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma PatientsJournal of Clinical Oncology, 2003
- Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in ScandinaviaInternational Journal of Cancer, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Histaminergic Regulation of Natural Killer Cell‐Mediated Clearance of Tumour Cells in MiceScandinavian Journal of Immunology, 1996